Aprogen Biologics Inc. (KRX:003060)
South Korea flag South Korea · Delayed Price · Currency is KRW
780.00
-6.00 (-0.76%)
At close: Mar 28, 2025, 3:30 PM KST

Aprogen Biologics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Net Income
-104,979-118,27012,6398,10311,253
Upgrade
Depreciation & Amortization
19,09021,3982,4042,0721,932
Upgrade
Loss (Gain) From Sale of Assets
-16.15151,537-3.1-53.08-593.48
Upgrade
Asset Writedown & Restructuring Costs
154.082,271264.152,134241.5
Upgrade
Loss (Gain) From Sale of Investments
9,934-34,724-1,380-1,623-2,476
Upgrade
Loss (Gain) on Equity Investments
29,047-75,012-1,353-352.2-5,375
Upgrade
Provision & Write-off of Bad Debts
0.01-24.29-2,224-26.23-1,532
Upgrade
Other Operating Activities
16,98031,1641,476-720.215,844
Upgrade
Change in Accounts Receivable
-2,2171,218-637.92-494.75902.78
Upgrade
Change in Inventory
-5,708-3,284-1,180-1,023-1,606
Upgrade
Change in Accounts Payable
662.83-2,373313.46-155.63272.35
Upgrade
Change in Income Taxes
----3.85
Upgrade
Change in Other Net Operating Assets
6,056-7,55015,410-14,088-779.66
Upgrade
Operating Cash Flow
-30,996-33,65125,728-6,2278,088
Upgrade
Operating Cash Flow Growth
----1033.22%
Upgrade
Capital Expenditures
-15,264-28,088-1,284-796.19-976.29
Upgrade
Sale of Property, Plant & Equipment
16.5316.8216.3666.7151.07
Upgrade
Cash Acquisitions
--9,223---
Upgrade
Divestitures
200-3,074--
Upgrade
Sale (Purchase) of Intangibles
-187.34-308.06-261.4-145.94-292.21
Upgrade
Investment in Securities
-12,262-79,69022,19775,048-70,507
Upgrade
Other Investing Activities
-24,22522,086-76,742-97,329-123,544
Upgrade
Investing Cash Flow
-51,722-95,206-53,001-23,156-195,268
Upgrade
Short-Term Debt Issued
53,95049,61020,500--
Upgrade
Long-Term Debt Issued
39,997114,611---
Upgrade
Total Debt Issued
93,947164,22120,500--
Upgrade
Short-Term Debt Repaid
-60,650-122,110-4,000--
Upgrade
Long-Term Debt Repaid
-61,594-353.06-262.55-349.3-410.3
Upgrade
Total Debt Repaid
-122,244-122,463-4,263-349.3-410.3
Upgrade
Net Debt Issued (Repaid)
-28,29741,75816,237-349.3-410.3
Upgrade
Issuance of Common Stock
115,75940,0000.24-235,376
Upgrade
Repurchase of Common Stock
-21.72-4,425---
Upgrade
Other Financing Activities
-2,46837,957-455.34-0.96-13,262
Upgrade
Financing Cash Flow
84,972115,28915,782-350.26221,704
Upgrade
Foreign Exchange Rate Adjustments
-11.6525.0411.02-24.83
Upgrade
Miscellaneous Cash Flow Adjustments
--0-0-
Upgrade
Net Cash Flow
2,253-13,555-11,465-29,72234,499
Upgrade
Free Cash Flow
-46,261-61,73924,444-7,0237,112
Upgrade
Free Cash Flow Margin
-68.66%-70.67%37.50%-12.43%13.34%
Upgrade
Free Cash Flow Per Share
-367.96-978.78604.74-176.20223.97
Upgrade
Cash Interest Paid
2,213151.0425.7789.51117.14
Upgrade
Cash Income Tax Paid
-31.26-2,4852,1151,810740.06
Upgrade
Levered Free Cash Flow
-24,02613,979104,474-97,245-29,721
Upgrade
Unlevered Free Cash Flow
-20,57916,272104,645-97,226-29,690
Upgrade
Change in Net Working Capital
-12,392-67,451-106,41495,87129,678
Upgrade
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.